Brief: Protagonist Therapeutics Q3 EPS USD 3.07
BRIEF-Protagonist Therapeutics Q3 EPS USD 3.07 Nov 05 (Reuters) - Protagonist Therapeutics Q3 operating expenses USD 56.078 million.
- Q3 net income USD 220.015 million
- Q3 license and collaboration revenue USD 274.41 million
- Q3 income from operations USD 218.332 million
Recent news on Protagonist Therapeutics
See all newsProtagonist Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Protagonist Therapeutics Q3 revenue surges on Takeda payments
Brief: Protagonist Therapeutics Q3 EPS USD 3.07
UK approves J&J's oral psoriasis pill
U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International